A Phase Ib Study of the Saftey and Pharmacokinetics of MPDL3280A (Anti-PD-L1 Antibody) Alone or in Combination with Lenalidomide in Patients with Multiple Myeloma (Relapsed and Post-Autologous Stem Cell Transplantation)
ID Number 15-1091Principal Investigator(s)
Hearn Jay Cho
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to test the safety of the combination of an experimental drug called MPDL3280A and lenalidomide (approved by the FDA) at different dose levels, and to find out what effects, good or bad, the combination of these drugs has on you. An experimental drug is not approved by the U.S. Food and Drug Administration or any other regulatory authority outside the United States.
Recruiting Patients: Yes